| Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus (NCT01471574) | Bristol-Myers Squibb | 2011-12-01 |
| Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C (NCT01448044) | Bristol-Myers Squibb | 2011-12-01 |
| Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease (NCT01466374) | Bristol-Myers Squibb | 2011-12-01 |
| Korean Post-marketing Surveillance for Reyataz® (NCT01450605) | Bristol-Myers Squibb | 2011-12-01 |
| Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications (NCT01455090) | Bristol-Myers Squibb | 2011-11-30 |
| Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (NCT01478048) | Bristol-Myers Squibb | 2011-11-30 |
| Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma (NCT01455103) | Bristol-Myers Squibb | 2011-11-01 |
| Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) (NCT01400451) | Bristol-Myers Squibb | 2011-11-01 |
| Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors (NCT01413906) | Bristol-Myers Squibb | 2011-11-01 |
| Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (NCT01452334) | Bristol-Myers Squibb | 2011-11-01 |
| Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC) (NCT03274141) | Bristol-Myers Squibb | 2011-10-31 |
| Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients (NCT01656343) | Bristol-Myers Squibb | 2011-10-31 |
| Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers (NCT01471704) | Bristol-Myers Squibb | 2011-10-01 |
| Korean Post-marketing Surveillance for Sprycel® (NCT01464047) | Bristol-Myers Squibb | 2011-10-01 |
| Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb (NCT01439204) | Bristol-Myers Squibb | 2011-10-01 |
| Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients (NCT01332227) | Bristol-Myers Squibb | 2011-10-01 |
| Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects (NCT02034591) | Bristol-Myers Squibb | 2011-10-01 |
| Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects (NCT01471717) | Bristol-Myers Squibb | 2011-10-01 |
| Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia (NCT01420783) | Bristol-Myers Squibb | 2011-10-01 |
| Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (NCT01363817) | Bristol-Myers Squibb | 2011-09-28 |
| Phase I Biomarker Study (BMS-936558) (NCT01358721) | Bristol-Myers Squibb | 2011-09-23 |
| Japanese Phase 1 Multiple Ascending Dose (MAD) Study (NCT01396252) | Bristol-Myers Squibb | 2011-09-01 |
| Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) (NCT01357655) | Bristol-Myers Squibb | 2011-09-01 |
| Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis (NCT01404585) | Bristol-Myers Squibb | 2011-09-01 |
| Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects (NCT01445795) | Bristol-Myers Squibb | 2011-09-01 |
| BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C (NCT01389323) | Bristol-Myers Squibb | 2011-09-01 |
| Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT01359657) | Bristol-Myers Squibb | 2011-09-01 |
| Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials (NCT01428063) | Bristol-Myers Squibb | 2011-09-01 |
| Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (NCT01335399) | Bristol-Myers Squibb | 2011-08-04 |
| Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects (NCT01404572) | Bristol-Myers Squibb | 2011-08-01 |
| Phase 2 Study of SAR302503 in Patients With Myelofibrosis (NCT01420770) | Bristol-Myers Squibb | 2011-08-01 |
| Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression (NCT01361555) | Bristol-Myers Squibb | 2011-08-01 |
| Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter (NCT01195727) | Bristol-Myers Squibb | 2011-07-26 |
| Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects (NCT02034578) | Bristol-Myers Squibb | 2011-07-01 |
| Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations (NCT01392703) | Bristol-Myers Squibb | 2011-07-01 |
| Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe (NCT01389310) | Bristol-Myers Squibb | 2011-07-01 |
| Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression (NCT01369095) | Bristol-Myers Squibb | 2011-07-01 |
| Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (NCT01239797) | Bristol-Myers Squibb | 2011-06-20 |
| Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care (NCT01359644) | Bristol-Myers Squibb | 2011-06-01 |
| Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis (NCT01340586) | Bristol-Myers Squibb | 2011-06-01 |
| BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) (NCT01354431) | Bristol-Myers Squibb | 2011-05-31 |
| Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients (NCT01335698) | Bristol-Myers Squibb | 2011-05-27 |
| Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) (NCT01394666) | Bristol-Myers Squibb | 2011-05-01 |
| Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden (NCT01356914) | Bristol-Myers Squibb | 2011-05-01 |
| Multiple Ascending Dose of BMS-911543 (NCT01236352) | Bristol-Myers Squibb | 2011-04-07 |
| Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression (NCT01309945) | Bristol-Myers Squibb | 2011-04-01 |
| Safety Study of Abatacept in Sweden (NCT01094795) | Bristol-Myers Squibb | 2011-03-31 |
| Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors (NCT01292655) | Bristol-Myers Squibb | 2011-03-03 |
| Comparative Tolerability of Protease Inhibitors (NCT01450618) | Bristol-Myers Squibb | 2011-03-01 |
| Crossover Post-herpetic Neuralgia (PHN) (NCT01305538) | Bristol-Myers Squibb | 2011-03-01 |
| Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis (NCT01294410) | Bristol-Myers Squibb | 2011-03-01 |
| Diabetic Peripheral Neuropathic Pain (DPNP) (NCT01314222) | Bristol-Myers Squibb | 2011-03-01 |
| Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (NCT01309932) | Bristol-Myers Squibb | 2011-03-01 |
| Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder (NCT01227668) | Bristol-Myers Squibb | 2011-03-01 |
| Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (NCT01489046) | Bristol-Myers Squibb | 2011-02-01 |
| Pediatric Catheter-related Thrombosis Imaging Study (NCT01137578) | Bristol-Myers Squibb | 2011-02-01 |
| Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes (NCT01290575) | Bristol-Myers Squibb | 2011-02-01 |
| Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection (NCT01232127) | Bristol-Myers Squibb | 2011-02-01 |
| Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin (NCT01285609) | Bristol-Myers Squibb | 2011-01-16 |
| Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone (NCT01241292) | Bristol-Myers Squibb | 2011-01-14 |
| Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting (NCT01236235) | Bristol-Myers Squibb | 2011-01-01 |
| Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma (NCT01245556) | Bristol-Myers Squibb | 2011-01-01 |
| Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients (NCT01356901) | Bristol-Myers Squibb | 2011-01-01 |
| Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) (NCT01218477) | Bristol-Myers Squibb | 2011-01-01 |
| Safety Study of Abatacept to Treat Rheumatoid Arthritis (NCT01247766) | Bristol-Myers Squibb | 2010-12-31 |
| Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors (NCT01225172) | Bristol-Myers Squibb | 2010-12-31 |
| Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (NCT01244750) | Bristol-Myers Squibb | 2010-12-02 |
| Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection (NCT01257204) | Bristol-Myers Squibb | 2010-12-01 |
| Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis (NCT01142726) | Bristol-Myers Squibb | 2010-12-01 |
| Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen (NCT01204762) | Bristol-Myers Squibb | 2010-11-01 |
| Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B) (NCT01240980) | Bristol-Myers Squibb | 2010-11-01 |
| Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma (NCT00803374) | Bristol-Myers Squibb | 2010-11-01 |
| PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) (NCT01099579) | Bristol-Myers Squibb | 2010-10-13 |
| Ph IIA Study (SOC +/- NS5B) (NCT01193361) | Bristol-Myers Squibb | 2010-10-01 |
| Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept (NCT01221636) | Bristol-Myers Squibb | 2010-10-01 |
| Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects (NCT01250366) | Bristol-Myers Squibb | 2010-10-01 |
| Effect of Diltiazem on Pharmacokinetics of BMS-914392 (NCT01211808) | Bristol-Myers Squibb | 2010-09-01 |
| Effect of BMS-914392 on Pharmacokinetics of Metoprolol (NCT01211821) | Bristol-Myers Squibb | 2010-09-01 |
| Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer (NCT01165216) | Bristol-Myers Squibb | 2010-09-01 |
| Drug-Drug Interaction Study With Rifampin (NCT01002079) | Bristol-Myers Squibb | 2010-08-01 |
| Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response (NCT01167244) | Bristol-Myers Squibb | 2010-08-01 |
| Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment (NCT01170962) | Bristol-Myers Squibb | 2010-08-01 |
| First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers (NCT01120457) | Bristol-Myers Squibb | 2010-08-01 |
| Safety Study of BMS-823778 in Subjects With Type 2 Diabetes (NCT01111955) | Bristol-Myers Squibb | 2010-07-01 |
| Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer (NCT01057810) | Bristol-Myers Squibb | 2010-07-01 |
| Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey (NCT01188278) | Bristol-Myers Squibb | 2010-07-01 |
| A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I (NCT01142700) | Bristol-Myers Squibb | 2010-07-01 |
| Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients (NCT01125189) | Bristol-Myers Squibb | 2010-07-01 |
| Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer (NCT01086267) | Bristol-Myers Squibb | 2010-07-01 |
| A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection (NCT01079806) | Bristol-Myers Squibb | 2010-06-30 |
| Experimental Study to Validate the Modified Glucose Disposal Test (NCT01152372) | Bristol-Myers Squibb | 2010-06-01 |
| Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer (NCT01068704) | Bristol-Myers Squibb | 2010-06-01 |
| Safety Study of BMS-823778 in Subjects With Hypercholesterolemia (NCT01112423) | Bristol-Myers Squibb | 2010-06-01 |
| Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics (NCT01166620) | Bristol-Myers Squibb | 2010-06-01 |
| Safety and Pharmacology Study of BMS-866949 (NCT01124344) | Bristol-Myers Squibb | 2010-05-01 |
| Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment (NCT01108705) | Bristol-Myers Squibb | 2010-05-01 |
| Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment (NCT01063036) | Bristol-Myers Squibb | 2010-05-01 |
| Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes (NCT01105429) | Bristol-Myers Squibb | 2010-05-01 |
| Safety Study of BMS-770767 in Subjects With Hypercholesterolemia (NCT01058083) | Bristol-Myers Squibb | 2010-05-01 |
| Safety Study of BMS-770767 in Subjects With Type 2 Diabetes (NCT01046422) | Bristol-Myers Squibb | 2010-05-01 |